This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Events OverviewITM Symposium on Actinium-225 Targeted Radionuclide Therapy at Theranostics World CongressITM Precision Oncology Symposium 2022ITM's Symposium at NuklearMedizin 20222nd ICPO Forum for Theranostics in Precision OncologyITM's ESMO 2021 Industry Satellite SymposiumITM Precision Oncology Symposium 2021COMPETE e-poster at AACR 2021

COMPETE e-poster at AACR 2021

ITM Presents Design for Ongoing Phase III COMPETE Trial with n.c.a. 177Lu-Edotreotide at AACR Annual Meeting 2021


Presentation information

Title: COMPETE Phase III Trial – Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide vs. Everolimus in Progressive GEP-NET

Abstract No: 5201

Session: Phase III Clinical Trials in Progress

Presenter: Mona M. Wahba, MD
Mona M. Wahba is available for questions and discussions via the chat box function of the AACR poster section and will respond within 24 hours. Meetings can also be requested using the AACR system.

The poster is available for Healthcare Professionals - please click here.